Search
Close this search box.

FDA Requires Updates to Labeling for Promethazine Hydrochloride Injection Products: Important Information

The Food and Drug Administration (FDA) has recently announced that it is requiring updates to the labeling for promethazine hydrochloride injection products. This decision comes as a result of new safety information regarding the potential risks associated with the use of these products.

Promethazine hydrochloride injection is a medication commonly used to treat various conditions such as nausea, vomiting, and motion sickness. It belongs to a class of drugs known as phenothiazines, which work by blocking certain receptors in the brain.

The updated labeling will now include a boxed warning, the FDA’s strongest warning, highlighting the risks of severe tissue injury, including gangrene, when this medication is administered incorrectly. The warning emphasizes the importance of proper administration techniques and cautions against intravenous administration.

Intravenous administration of promethazine hydrochloride injection has been associated with serious complications, including tissue damage, severe chemical irritation, and even amputation. These risks are particularly high when the medication is injected into an artery or when it comes into contact with arterial blood.

To minimize the risk of these complications, healthcare professionals are advised to use alternative routes of administration whenever possible. If intravenous administration is necessary, extreme caution should be exercised to ensure proper needle placement and to avoid injecting the medication into an artery.

The FDA also recommends that healthcare professionals closely monitor patients for signs and symptoms of tissue injury following the administration of promethazine hydrochloride injection. These may include pain, swelling, discoloration, or numbness at the injection site. If any of these symptoms occur, immediate medical attention should be sought.

Patients who are prescribed promethazine hydrochloride injection should be informed about the potential risks associated with this medication. They should be instructed to report any unusual symptoms or side effects to their healthcare provider promptly.

It is important to note that promethazine hydrochloride injection is not approved for use in children under the age of two. The safety and effectiveness of this medication in pediatric patients have not been established, and its use in this population should be avoided.

The FDA’s decision to require updates to the labeling for promethazine hydrochloride injection products is aimed at improving patient safety and ensuring that healthcare professionals are aware of the potential risks associated with this medication. By providing clear and concise information about the proper administration techniques and potential complications, the FDA hopes to minimize the occurrence of severe tissue injury and other adverse events.

In conclusion, the FDA has mandated updates to the labeling for promethazine hydrochloride injection products to include a boxed warning highlighting the risks of severe tissue injury. Healthcare professionals are advised to use alternative routes of administration whenever possible and exercise extreme caution when administering this medication intravenously. Patients should be informed about the potential risks and instructed to report any unusual symptoms or side effects to their healthcare provider. This regulatory action by the FDA aims to enhance patient safety and prevent serious complications associated with the use of promethazine hydrochloride injection.